Literature DB >> 18179918

Consequences of a selective approach toward pulmonary valve replacement in adult patients with tetralogy of Fallot and pulmonary regurgitation.

Folkert J Meijboom1, Jolien W Roos-Hesselink, Jackie S McGhie, Silja E C Spitaels, Ron T van Domburg, Lisbeth M W J Utens, Maarten L Simoons, Ad J J C Bogers.   

Abstract

OBJECTIVE: The aim of the study was to assess the long-term results of a selective policy toward pulmonary valve replacement in adult patients with repaired tetralogy of Fallot and severe pulmonary regurgitation.
METHODS: Sixty-seven patients with tetralogy of Fallot were followed up from 15 +/- 3 years until 27 +/- 3 years after surgery.
RESULTS: Twenty-two patients had mild-to-moderate pulmonary regurgitation. No significant changes occurred in the follow-up period. Of 45 patients with severe pulmonary regurgitation and severe right ventricular dilatation, 28 (62%) remained free of symptoms and did not undergo pulmonary valve replacement. No changes in right ventricular size or exercise capacity were found. In 3 (11%) of 28 patients, QRS duration increased to more than 180 ms. Seventeen patients had symptoms and underwent pulmonary valve replacement: 9 (54%) of 17 patients improved clinically and echocardiographically, and QRS duration shortened postoperatively. Right ventricular dimensions did not regress despite pulmonary valve replacement in 8 patients.
CONCLUSION: Refraining from pulmonary valve replacement in asymptomatic patients led to no measurable deterioration in 25 (89%) of 28 patients. Referring symptomatic patients for pulmonary valve replacement led to an improvement in 9 (53%) of 17 patients. In 11 (24%) of 45, a selective approach led to questionable or unsatisfactory results.

Entities:  

Mesh:

Year:  2008        PMID: 18179918     DOI: 10.1016/j.jtcvs.2007.07.030

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  8 in total

1.  Randomized trial of pulmonary valve replacement with and without right ventricular remodeling surgery.

Authors:  Tal Geva; Kimberlee Gauvreau; Andrew J Powell; Frank Cecchin; Jonathan Rhodes; Judith Geva; Pedro del Nido
Journal:  Circulation       Date:  2010-09-14       Impact factor: 29.690

2.  Tetralogy of Fallot: Current surgical perspective.

Authors:  Tom R Karl
Journal:  Ann Pediatr Cardiol       Date:  2008-07

3.  Mechanical stress is associated with right ventricular response to pulmonary valve replacement in patients with repaired tetralogy of Fallot.

Authors:  Dalin Tang; Chun Yang; Pedro J Del Nido; Heng Zuo; Rahul H Rathod; Xueying Huang; Vasu Gooty; Alexander Tang; Kristen L Billiar; Zheyang Wu; Tal Geva
Journal:  J Thorac Cardiovasc Surg       Date:  2015-10-03       Impact factor: 5.209

Review 4.  Repaired tetralogy of Fallot: the roles of cardiovascular magnetic resonance in evaluating pathophysiology and for pulmonary valve replacement decision support.

Authors:  Tal Geva
Journal:  J Cardiovasc Magn Reson       Date:  2011-01-20       Impact factor: 5.364

Review 5.  Pulmonary Regurgitation after Tetralogy of Fallot Repair: A Diagnostic and Therapeutic Challenge.

Authors:  Selvi Senthilnathan; Andreea Dragulescu; Luc Mertens
Journal:  J Cardiovasc Echogr       Date:  2013 Jan-Mar

6.  Tetralogy of fallot: a surgical perspective.

Authors:  Tom R Karl
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2012-08-03

7.  Timing of pulmonary valve replacement in patients with corrected Fallot to prevent QRS prolongation.

Authors:  Jamie L R Romeo; Johanna J M Takkenberg; Judith A A E Cuypers; Natasha M S de Groot; Pieter van de Woestijne; Nico Bruining; Ad J J C Bogers; M Mostafa Mokhles
Journal:  Eur J Cardiothorac Surg       Date:  2020-09-01       Impact factor: 4.191

8.  Multi-plane echocardiographic assessment of right ventricular function in adults with repaired Tetralogy of Fallot.

Authors:  Daniel J Bowen; An M van Berendoncks; Jackie S McGhie; Jolien W Roos-Hesselink; Annemien E van den Bosch
Journal:  Int J Cardiovasc Imaging       Date:  2021-05-18       Impact factor: 2.357

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.